• Explore /
  • Poster
  • / CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.

CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.

Abstract Video & Slides Poster

Authors

null

Sosana Delimpasi

Department of Hematology and Lymphoma, Evangelismos Hospital, Athens, Greece

Sosana Delimpasi , HANG QUACH , Michele Cavo , P. Joy Ho , Cindy Lee , Armando Santoro , Rik Schots , Philip Vlummens , Dok Hyun Yoon , Sung-Soo Yoon , Cedric Dos Santos , Divya Samineni , Jiangeng Huang , Kristin Wehrman , Upen Patil , Semira Sheikh , Meletios A. Dimopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

26168155

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS8070)

DOI

10.1200/JCO.2022.40.16_suppl.TPS8070

Abstract #

TPS8070

Poster Bd #

492a

Abstract Disclosures

Similar Posters

First Author: Ravi Vij

First Author: Adam D. Cohen

First Author: Krish Patel

First Author: Jeroen Elassaiss-Schaap